[Emergency prevention of influenza with remantadin].
Prophylactic efficacy of remantadin was studied during influenza epidemics caused by types A (H3N2) and B viruses. More than 15,000 persons were observed. Daily administration of remantadin ensured a decrease in influenza A (but not influenza B) morbidity 1.5-4.5 times in different groups (planned prophylaxis) and 6.5-10.3 times in family foci (focal prophylaxis). The protective effect of remantadin is mainly due to its capacity of suppressing the toxic manifestations of influenza infection, which is accompanied by a decrease in the frequency and duration of clinically pronounced disease and an increase in the proportion of asymptomatic forms.
D000218:Adamantane / Q000031:analogs & derivatives*; D000293:Adolescent; D000328:Adult; D004196:Disease Outbreaks / Q000517:prevention & control*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007252:Influenza Vaccines / Q000008:administration & dosage; D007251:Influenza, Human / Q000517:prevention & control*; D008297:Male; D010919:Placebos; D012299:Rimantadine / Q000627:therapeutic use*; D014586:USSR
D007252:Influenza Vaccines; D010919:Placebos; D012299:Rimantadine; D000218:Adamantane
Ekstrennaia profilaktika grippa remantadinom.